Xsensio SA, a Swiss deep-tech company focused on near-real-time continuous biochemical monitoring, announced the closing of a $7 million oversubscribed Series A financing round to accelerate the clinical deployment of its wearable biosensing technology.
The round was led by WI Harper, with participation from Privilège Ventures, the European Innovation Council, and private investors across the United States, Europe, and Asia.
The new capital will support the development and clinical validation of Xsensio’s Lab-on-Skin wearable biosensing platform, which is designed to deliver dynamic, multi-modal biochemical data to clinicians in real time. The company said the technology aims to provide continuous biochemical insights at the point of care, a capability that has historically been unavailable in clinical environments.
In conjunction with the funding, Xsensio also announced a long-term collaboration with Texas Instruments to strengthen its semiconductor integration and manufacturing scalability. The partnership is expected to enhance CMOS integration, miniaturization, and large-scale manufacturability of Xsensio’s biosensing systems as the company moves toward broader clinical deployment.
Xsensio was spun out of leading academic research institutions and collaborates with reference hospitals and industrial partners to advance personalized and preventive healthcare. The company was recognized by TIME as one of the World’s Top HealthTech Companies of 2025.
KEY QUOTES:
“This Series A marks a pivotal step in translating continuous biochemical monitoring into real clinical environments. For the first time, clinicians can access key continuous biochemical data in real time, information that has historically been unavailable at the point of care. This capability has the potential to fundamentally improve how patients are monitored and treated.”
Esmeralda Megally, CEO Of Xsensio SA
“Our collaboration with Texas Instruments significantly strengthens our path to advanced, scalable semiconductor technology. By combining our biosensing innovation with world-class semiconductor expertise, we are building a platform designed not only for clinical impact, but also for reliable, cost-effective deployment.”
Adrian Ionescu, CTO Of Xsensio SA
“We believe Xsensio is defining a new category in wearable biosensing. Given the company’s strong progress and market potential, we are excited to be leading this investment round.”
Wilson Wu, Partner At WI Harper
“Continuous biochemical monitoring represents a major shift from intermittent measurements to real-time insight, and Xsensio is uniquely positioned to lead this transformation.”
Jaqueline Ruedin Rüsch, Chair Of The Board, Xsensio SA
